{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:35:16Z","timestamp":1793090116747,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T00:00:00Z","timestamp":1680566400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.biopha.2023.114663","type":"journal-article","created":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T16:00:12Z","timestamp":1680710412000},"page":"114663","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["In vivo assessment of the pharmacokinetic interactions between donafenib and dapagliflozin, donafenib and canagliflozin in rats"],"prefix":"10.1016","volume":"162","author":[{"given":"Xueru","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caihui","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhao","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejiao","family":"Xun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanjun","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.biopha.2023.114663_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.biopha.2023.114663_bib2","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13046-019-1094-2","article-title":"Clinical development of targeted and immune based anti-cancer therapies","volume":"38","author":"Seebacher","year":"2019","journal-title":"J. Exp. Clin. Cancer Res"},{"issue":"6","key":"10.1016\/j.biopha.2023.114663_bib3","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1159\/000511001","article-title":"Recent advances in systemic therapy for hepatocellular carcinoma in an aging Societ:2020 update","volume":"9","author":"Kudo","year":"2020","journal-title":"Liver Cancer"},{"issue":"16","key":"10.1016\/j.biopha.2023.114663_bib4","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1007\/s40265-021-01603-0","article-title":"Donafenib: first approval","volume":"81","author":"Keam","year":"2021","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.biopha.2023.114663_bib5","doi-asserted-by":"crossref","first-page":"737","DOI":"10.21037\/hbsn-21-304","article-title":"Donafenib as a first-line monotherapy for advanced hepatocellular carcinoma","volume":"10","author":"Zhang","year":"2021","journal-title":"Hepatobiliary Surg. Nutr."},{"issue":"27","key":"10.1016\/j.biopha.2023.114663_bib6","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1200\/JCO.21.00163","article-title":"Donafenib versus sorafenib in first-line treatment of unresectable or metastatic hepatocellular carcinoma: a randomized, open-label, parallel-controlled phase II-III trial","volume":"39","author":"Qin","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2023.114663_bib7","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00280-020-04031-1","article-title":"A Phase I dose-escalation, pharmacokinetics and food-effect study of oral donafenib in patients with advanced solid tumours","volume":"85","author":"Li","year":"2020","journal-title":"Cancer Chemother. Pharmcol."},{"key":"10.1016\/j.biopha.2023.114663_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Altas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res Clin. Pr."},{"key":"10.1016\/j.biopha.2023.114663_bib9","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2147\/CMAR.S188238","article-title":"Type 2 diabetes mellitus increases the risk of hepatocellular carcinoma in subjects with chronic hepatitis B virus infection: a meta-analysis and systematic review","volume":"11","author":"Tan","year":"2019","journal-title":"Cancer Manag Res"},{"issue":"5","key":"10.1016\/j.biopha.2023.114663_bib10","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1002\/hep.29660","article-title":"Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: Results from two prospective cohort studies","volume":"67","author":"Simon","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2023.114663_bib11","doi-asserted-by":"crossref","first-page":"5202684","DOI":"10.1155\/2017\/5202684","article-title":"Diabetes mellitus and risk of hepatocellular carcinoma","volume":"2017","author":"Li","year":"2017","journal-title":"Biomed. Res Int"},{"issue":"8","key":"10.1016\/j.biopha.2023.114663_bib12","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1002\/cncr.24982","article-title":"Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma","volume":"116","author":"Hassan","year":"2010","journal-title":"Cancer"},{"issue":"16","key":"10.1016\/j.biopha.2023.114663_bib13","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.3390\/ijerph16162965","article-title":"SGLT2 inhibitors: A review of their antidiabetic and cardioprotective effects","volume":"16","author":"Tentolouris","year":"2019","journal-title":"Int J. Environ. Res Public Health"},{"key":"10.1016\/j.biopha.2023.114663_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106261","article-title":"The effects of sodium-glucose cotransporter 2 inhibitors on hepatocellular carcinoma: From molecular mechanisms to potential clinical implications","volume":"181","author":"Arvanitakis","year":"2022","journal-title":"Pharmacol. Res"},{"issue":"1","key":"10.1016\/j.biopha.2023.114663_bib15","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3390\/metabo11010022","article-title":"Sodium-glucose cotransporter-2 inhibitors for treatment of nonalcoholic fatty liver disease: A meta-analysis of randomized controlled trials","volume":"11","author":"Mantovani","year":"2020","journal-title":"Metabolites"},{"issue":"7","key":"10.1016\/j.biopha.2023.114663_bib16","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s13300-022-01280-6","article-title":"Beyond the glycaemic control of dapagliflozin: Impact on arterial stiffness and macroangiopathy","volume":"13","author":"Gonz\u00e1lez-Clemente","year":"2022","journal-title":"Diabetes Ther."},{"issue":"6","key":"10.1016\/j.biopha.2023.114663_bib17","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/s41419-019-1646-6","article-title":"Canagliflozin inhibits growth of hepatocellular carcinoma via blocking glucose-influx-induced \u03b2-catenin activation","volume":"10","author":"Hung","year":"2019","journal-title":"Cell Death Dis."},{"issue":"2","key":"10.1016\/j.biopha.2023.114663_bib18","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/dom.13520","article-title":"Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"21","author":"Shimizu","year":"2019","journal-title":"Diabetes Obes. Metab."},{"issue":"1","key":"10.1016\/j.biopha.2023.114663_bib19","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40262-013-0104-3","article-title":"Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose Co-transporter type 2","volume":"53","author":"Kasichayanula","year":"2014","journal-title":"Clin. Pharm."},{"issue":"3","key":"10.1016\/j.biopha.2023.114663_bib20","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1124\/dmd.109.029165","article-title":"In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans","volume":"38","author":"Obermeier","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.biopha.2023.114663_bib21","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/nyas.12852","article-title":"a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus","volume":"1358","author":"Rosenthal","year":"2015","journal-title":"Ann. N. Y Acad. Sci."},{"issue":"10","key":"10.1016\/j.biopha.2023.114663_bib22","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1124\/dmd.115.065870","article-title":"Inhibition of human UDP-glucuronosyltransferase enzymes by canagliflozin and dapagliflozin: Implications for drug-drug interactions","volume":"43","author":"Pattanawongsa","year":"2015","journal-title":"Drug Metab. Dispos."},{"issue":"5","key":"10.1016\/j.biopha.2023.114663_bib23","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1124\/dmd.113.056440","article-title":"Metabolism and excretion of canagliflozin in mice, rats, dogs, and humans","volume":"42","author":"Mamidi","year":"2014","journal-title":"Drug Metab. Dispos."},{"issue":"5","key":"10.1016\/j.biopha.2023.114663_bib24","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/bcp.13186","article-title":"In vitro and physiologically\u2010based pharmacokinetic based assessment of drug\u2013drug interaction potential of canagliflozin","volume":"83","author":"Mamidi","year":"2017","journal-title":"Br. J. Clin. Pharm."},{"issue":"2","key":"10.1016\/j.biopha.2023.114663_bib25","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/bcp.12496","article-title":"Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations","volume":"79","author":"Teo","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2023.114663_bib26","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/978-981-13-7647-4_5","article-title":"Transporter-mediated drug-drug interactions and their significance","volume":"1141","author":"Liu","year":"2019","journal-title":"Adv. Exp. Med Biol."},{"issue":"1","key":"10.1016\/j.biopha.2023.114663_bib27","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1124\/dmd.104.001321","article-title":"Analysis of substrate specificities and tissue expression of rat UDP-glucuronosyltransferases UGT1A7 and UGT1A8","volume":"33","author":"Webb","year":"2005","journal-title":"Drug Metab. Dispos."},{"issue":"6","key":"10.1016\/j.biopha.2023.114663_bib28","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.3390\/molecules23061487","article-title":"Upregulation of UDP-glucuronosyltransferases 1a1 and 1a7 are involved in altered puerarin pharmacokinetics in type II diabetic rats","volume":"23","author":"Dong","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.biopha.2023.114663_bib29","unstructured":"US Food and Drug Administration Guidance for Industry: Bioanalytical Method Validation, 2018. Rockville, MD, USA: US Department of Health and Human Services, US FDA, Center for Drug Evaluation and Research; 2018. \u3008https:\/\/www.fda.gov\/fles\/drugs\/published\/\u3009 Bioanalytical-Method-Validation-Guidance-for-Industry.pdf."},{"issue":"5","key":"10.1016\/j.biopha.2023.114663_bib30","doi-asserted-by":"crossref","first-page":"101","DOI":"10.21315\/mjms2017.24.5.11","article-title":"Sample size calculation in animal studies using resource equation approach","volume":"24","author":"Arifin","year":"2017","journal-title":"Malays. J. Med Sci."},{"issue":"1","key":"10.1016\/j.biopha.2023.114663_bib31","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1186\/s12885-022-09649-3","article-title":"A comprehensive evaluation of potentially significant drug-drug, drug-herb, and drug-food interactions among cancer patients receiving anticancer drugs","volume":"22","author":"Koni","year":"2022","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2023.114663_bib32","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.critrevonc.2013.08.007","article-title":"Drug interactions with solid tumour-targeted therapies","volume":"89","author":"Thomas-Schoemann","year":"2014","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"3","key":"10.1016\/j.biopha.2023.114663_bib33","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1124\/dmd.111.042770","article-title":"Deuterium isotope effects on drug pharmacokinetics. I. system-dependent effects of specific seuteration with aldehyde oxidase cleared drugs","volume":"40","author":"Sharma","year":"2012","journal-title":"Drug Metab. Dispos."},{"issue":"1","key":"10.1016\/j.biopha.2023.114663_bib34","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1517\/17425255.2015.986457","article-title":"Pharmacokinetics, pharmacodynamics and clinical efficacy of dapagliflozin for the treatment of type 2 diabetes","volume":"11","author":"Maranghi","year":"2015","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"19","key":"10.1016\/j.biopha.2023.114663_bib35","doi-asserted-by":"crossref","first-page":"6190","DOI":"10.3390\/molecules27196190","article-title":"Development of UPLC-MS\/MS Method to study the pharmacokinetic interaction between sorafenib and dapagliflozin in rats","volume":"27","author":"He","year":"2022","journal-title":"Molecules"},{"issue":"6","key":"10.1016\/j.biopha.2023.114663_bib36","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1124\/dmd.112.048181","article-title":"Sorafenib hepatobiliary disposition: mechanisms of hepatic uptake and disposition of generated metabolites","volume":"41","author":"Swift","year":"2013","journal-title":"Drug Metab. Dispos."},{"issue":"8","key":"10.1016\/j.biopha.2023.114663_bib37","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1016\/S1470-2045(13)70579-5","article-title":"Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective","volume":"15","author":"van Leeuwen","year":"2014","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.biopha.2023.114663_bib38","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s40262-015-0285-z","article-title":"Clinical pharmacokinetic, pharmacodynamic, and drug\u2013drug interaction profile of canagliflozin, a sodium-glucose co-transporter 2 inhibitor","volume":"54","author":"Devineni","year":"2015","journal-title":"Clin. Pharmacokinet."},{"issue":"3","key":"10.1016\/j.biopha.2023.114663_bib39","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/dom.12024","article-title":"Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin","volume":"15","author":"Kasichayanula","year":"2013","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.biopha.2023.114663_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110530","article-title":"In vivo assessment of potential for UGT-inhibition-based drug-drug interaction between sorafenib and tapentadol","volume":"130","author":"Karbownik","year":"2020","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.biopha.2023.114663_bib41","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.bcp.2017.01.002","article-title":"Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemia","volume":"129","author":"Miners","year":"2017","journal-title":"Biochem Pharm."},{"issue":"17","key":"10.1016\/j.biopha.2023.114663_bib42","doi-asserted-by":"crossref","first-page":"5419","DOI":"10.3390\/molecules27175419","article-title":"Pharmacokinetic interactions between canagliflozin and sorafenib or lenvatinib in rats","volume":"27","author":"Cui","year":"2022","journal-title":"Molecules"},{"issue":"7","key":"10.1016\/j.biopha.2023.114663_bib43","doi-asserted-by":"crossref","first-page":"651","DOI":"10.3109\/00498254.2015.1109160","article-title":"The drug-drug interaction of sorafenib mediated by P-glycoprotein and CYP3A4","volume":"46","author":"Wang","year":"2016","journal-title":"Xenobiotica"},{"issue":"2","key":"10.1016\/j.biopha.2023.114663_bib44","doi-asserted-by":"crossref","first-page":"115","DOI":"10.5414\/CP202158","article-title":"Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants","volume":"53","author":"Devineni","year":"2015","journal-title":"Int J. Clin. Pharmacol. Ther."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223004511?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223004511?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T13:48:16Z","timestamp":1778248096000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332223004511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":44,"alternative-id":["S0753332223004511"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2023.114663","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vivo assessment of the pharmacokinetic interactions between donafenib and dapagliflozin, donafenib and canagliflozin in rats","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2023.114663","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"114663"}}